Not yet recruiting
Barth syndrome
Not yet recruitingEfficacy and Safety of Daily Subcutaneous Elamipretide Trihydrochloride Injections in Patients with Barth Syndrome (Phase 3b/4 Randomized Trial)
Investigational
Efficacy and Safety of Daily Subcutaneous Elamipretide Trihydrochloride Injections in Patients with Barth Syndrome (Phase 3b/4 Randomized Trial)
Investigational
- Disease:Barth syndrome
- Substances:Elamipretide Trihydrochloride
Countries:
France
France- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Elamipretide Trihydrochloride
- Sponsor:Stealth Biotherapeutics Inc.



